In light of evidence of the anti-immunogenic effects of chronic IFN-γ stimulation16,17, any future study of this drug in cancer patients should start at doses of 50 mcg/m2 or less, with consideration of less frequent dosing or alternative schedules. This evidence concerns the gene IFNG and cancer.